Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Human pharmacological activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon)

John G McHutchison, Duke University, Durham, NC; Bruce R Bacon, Saint Louis University School of Medicine, Saint Louis MO; Stuart C Gordon, William Beaumont Hospital, Royal Oak, MI; Nezam H Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Durham, NC; Arthur M Krieg, Susan Efler, Mohammed Al-Adhami, Heather L Davis, Tess K Schmalback, Coley Pharmaceutical Group, Inc. Wellesley, MA. Human pharmacological activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon). Hepatology The official Journal of the American Association for the Study of Liver Disease. 2004; 40(4):697A.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.